ospemifene is a selective estrogen receptor modulator serm acting similarly to an estrogen on the vaginal epithelium building vaginal wall thickness which in turn reduces the pain associated with dyspareunia dyspareunia is most commonly caused by vulvar and vaginal atrophy the medication was approved by the fda in february 2013 and by the european commission for marketing in the eu in january 2015 ospemifene is used to treat dyspareunia in the us it is indicated for the treatment of moderate to severe dyspareunia a symptom of vulvar and vaginal atrophy vva due to menopause in the eu it is indicated for the treatment of moderate to severe symptomatic vva in post menopausal women who are not candidates for local vaginal oestrogen therapy it is available as a 60 mg tablet that is taken by mouth once a day the fact that ospemifene can be taken orally is advertised as an advantage over other products that are topically applied in the vaginal canal ospemifene has not demonstrated any effects on libido arousal duration of intercourse or quality of orgasm in controlled clinical trials women with undiagnosed abnormal genital bleeding known or suspected estrogen dependent neoplasia active or history of deep vein